Amylyx Pharmaceuticals Faces Multiple Class Action Lawsuits

Investors allege misleading statements regarding the commercial prospects of ALS treatment RELYVRIO.

Multiple law firms have filed class action lawsuits against Amylyx Pharmaceuticals, Inc. (AMLX), alleging securities fraud.
The lawsuits cover the period between November 11, 2022, and November 8, 2023, seeking to recover losses for investors.
Claims focus on overstated commercial prospects of RELYVRIO, a treatment for ALS, and issues with patient discontinuation and prescription rates.
Amylyx's stock price fell approximately 31.89% following the disclosure of financial results and concerns over RELYVRIO's performance.
Investors have until early April 2024 to join the class action and potentially recover losses.